Published in
Elsevier, European Urology, 2(78), p. 184-192, 2020
DOI: 10.1016/j.eururo.2020.03.001
Links
Tools
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial
Journal article published in 2020 by
David P. Dearnaley,
Daniel R. Saltzstein,
John E. Sylvester,
Lawrence Karsh,
Bryan A. Mehlhaff,
Christopher Pieczonka 
,
James L. Bailen,
Hongliang Shi ,
Zhan Ye,
Hélène M. Faessel,
Huamao Lin,
Yanyan Zhu,
Fred Saad ,
David B. MacLean,
Neal D. Shore
,
James L. Bailen,
Hongliang Shi ,
Zhan Ye,
Hélène M. Faessel,
Huamao Lin,
Yanyan Zhu,
Fred Saad ,
David B. MacLean,
Neal D. Shore
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 